Prognostic value of Asymmetric dimethylarginine in patients with acute coronary syndrome

Abstract

Atherosclerosis is the primary cause of ACS, mostly occurring from the disruption of atherosclerotic plaque in a coronary artery stimulating platelet aggregation and thrombus formation (Coven et al., 2016). Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells. It is closely related to L-arginine, a conditionally essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide (NO), a key chemical involved in normal endothelial function (Vallance et al., 1992). ADMA inhibits the three isoforms of NOS, and it can uncouple the enzyme, generate superoxides, and it interfaces with other targets in the cell (Pou et al., 1999). ADMA is now known to be a mediator molecule of the adverse vascular effects of many other factors and markers of cardiovascular risk (Vallance et al., 1992). The aim of the study was to determine the value